Curis (CRIS) Total Non-Current Liabilities (2010 - 2026)
Curis' (CRIS) quarterly Total Non-Current Liabilities came in at $15.1 million in Q1 2026, down 29.7% YoY from $21.5 million in Q1 2025, and up 3.99% on a QoQ basis from $14.5 million in Q4 2025.
Curis (CRIS) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Total Non-Current Liabilities data on file, last reported at $15.1 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 29.7% year-over-year to $15.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.1 million (down 29.7% YoY) and the FY2025 annual result came in at $14.5 million, down 29.75% from the prior year.
- Total Non-Current Liabilities rose to $15.1 million in Q1 2026, from $14.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $24.0 million in Q3 2024 to a low of $10.6 million in Q1 2023.
- A 5-year average of $18.0 million and a median of $19.1 million in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 101.05% — and 2025, when it dropped 29.75%.
- Tracing CRIS's Total Non-Current Liabilities over 5 years: stood at $19.1 million in 2022, then increased by 23.28% to $23.5 million in 2023, then declined by 12.19% to $20.6 million in 2024, then dropped by 29.75% to $14.5 million in 2025, then climbed by 3.99% to $15.1 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $15.1 million (Q1 2026), $14.5 million (Q4 2025), and $20.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Curis | 3.44 Mn | -2.18 Mn | - | 13.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.08 Mn |
| Dec 31, 2025 | 14.50 Mn |
| Sep 30, 2025 | 20.65 Mn |
| Jun 30, 2025 | 20.42 Mn |
| Mar 31, 2025 | 21.46 Mn |
| Dec 31, 2024 | 20.65 Mn |
| Sep 30, 2024 | 24.00 Mn |
| Jun 30, 2024 | 21.68 Mn |
| Mar 31, 2024 | 21.23 Mn |
| Dec 31, 2023 | 23.51 Mn |
| Sep 30, 2023 | 15.54 Mn |
| Jun 30, 2023 | 11.85 Mn |
| Mar 31, 2023 | 10.56 Mn |
| Dec 31, 2022 | 19.07 Mn |
| Sep 30, 2022 | 16.84 Mn |
| Jun 30, 2022 | 15.54 Mn |
| Mar 31, 2022 | 12.63 Mn |
| Dec 31, 2021 | 17.80 Mn |
| Sep 30, 2021 | 14.01 Mn |
| Jun 30, 2021 | 12.58 Mn |